Thymulin

No study in the cited record has given thymulin to a person. The human data that does exist measured the body's own thymulin: in 14 adults with mild zinc deficiency, serum thymulin activity was low and returned to normal when zinc was restored, and in a placebo-controlled study of 27 people with Crohn's disease, plasma thymulin activity rose only in the group given the higher zinc dose.

That makes thymulin a well characterised hormone with a thin case as a product. Its activity depends on a zinc ion held inside the molecule, so what people have shown is that zinc status moves the measurement. What happens when the peptide itself is injected has been studied in rats, partly with a synthetic analogue rather than thymulin itself.

Thymulin is a nine amino acid peptide made by the epithelial cells of the thymus. It was first described in the early 1970s under the name facteur thymique sérique, originally isolated from pig serum, and its sequence is <Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn.

The peptide binds zinc one to one, and only the zinc-bound form is active. Both forms circulate. When zinc runs short, the inactive form predominates, which means a low thymulin reading can reflect either less peptide or less zinc to switch it on.

A Hormone With a Metal Switch

When the original research group stripped zinc from natural or synthetic thymulin with a chelating resin, its biological activity disappeared, and adding zinc chloride back restored it completely. The antibodies that recognise thymulin also stopped binding once the zinc was gone and bound again when it was returned. The zinc is part of the hormone's shape, not a helper elsewhere in a pathway.

The thymic cells that make thymulin contain both zinc and metallothionein, a zinc-binding protein, which points to the hormone leaving the cell already in its active form.

What the Active Hormone Does

Zinc-bound thymulin induces T-cell differentiation inside and outside the thymus. It also sits in a two-way relationship with the pituitary: growth hormone, prolactin and thyroid status influence thymulin levels, and thymulin in turn acts on pituitary cells. In rats, thymulin injected into the brain during experimentally induced inflammation showed anti-inflammatory and pain-reducing effects.

Serum thymulin is highest at birth, holds steady until roughly age 15 to 20, and then declines progressively. In aged mice, fewer thymic cells contained the hormone, so part of that decline is reduced production rather than zinc alone.

Most of the overreach here comes from borrowing evidence that belongs to something else.

Borrowing another molecule's trials. Several thymus-derived extracts and peptides have human trial records. Thymulin is a specific nine-residue, zinc-dependent hormone, and a trial of a different thymic product says nothing about it. The first check on any citation is which substance was actually given.

Turning a zinc finding into a peptide finding. In both human studies, the thing given was zinc, and the thing that rose was the activity of thymulin the body already made. Prasad's group restored activity simply by adding zinc to serum in a test tube, which shows the peptide was present and inactive. That result argues for zinc status as the variable, not for a shortage of peptide.

Reading a marker as an outcome. Higher thymulin activity is a change in a blood measurement. In the Crohn's study, lymphocyte subsets did not move even when thymulin activity did, and neither study measured infections, disease activity or any clinical result tied to the hormone.

Treating age-related decline as a deficiency to fix. Serum thymulin falls from early adulthood onward and production in the thymus drops with it. Nobody has tested in people whether raising it from outside changes immune function, ageing or anything else.

Promoting rat pain data to human use. The strongest anti-inflammatory result came from an analogue called PAT, in rats, with endotoxin as the trigger. That is a model, not a clinical indication.

There is no human safety data on thymulin as an administered compound, because no cited study gave it to a person. Tolerability, adverse effects and long-term exposure are all unknown in people.

The closest safety observation is from rats: the analogue PAT produced no evident changes in physiological parameters or normal behaviour at any dose tested. That is a single short animal study of a related peptide, not a safety profile.

Thymulin acetate is listed in Category 3 of the FDA's 503A nominations, meaning it was nominated for the compounding list with insufficient supporting information to evaluate. Category 3 substances do not receive the enforcement policy that applies to Category 1, and FDA states it would consider action against a compounder using them. It is not an FDA-approved drug. WADA does not name thymulin on its 2026 Prohibited List, but S0 prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, so absence from the list is not permission.

What the evidence supports: thymulin is a real thymic hormone whose activity depends on bound zinc. In people with low zinc, measured thymulin activity is low and comes back when zinc status improves, shown in 14 adults without a control group and in 27 Crohn's patients with one. In rats, an analogue of thymulin reduced inflammatory pain and cytokines.

What it does not support: any statement about what injected thymulin does in a human body, whether it is safe, or whether raising thymulin activity improves immunity or any health outcome. Those questions have not been studied. A zinc supplementation study describing what it measured is also not a recommendation for anyone to take zinc.

Not a peptide with human administration data. The human studies measured the body's own thymulin and gave zinc or placebo. None gave thymulin itself, so there are no human efficacy or safety results.

Not thymosin alpha-1. That is a separately named thymic peptide with its own evidence, covered on its own page. Thymulin is the nine-residue zinc-binding hormone formerly called facteur thymique sérique, and the two records do not transfer.

Not a thymus extract. Extracts and preparations made from animal thymus tissue are different products, and trials of them are not trials of this peptide.

Not proof that zinc and thymulin are interchangeable. Zinc raised thymulin activity in zinc-deficient people. That shows thymulin activity tracks zinc status, not that supplying the peptide would do what restoring zinc did.

Not an approved drug. FDA lists thymulin acetate in Category 3 of the 503A nominations, and no regulator has approved it for human therapeutic use.

I like thymulin as biology. A hormone that does nothing until a zinc ion locks it into shape, and that you can switch back on in a test tube by adding zinc to someone's serum, is a clean and memorable piece of physiology. The Prasad study is careful work and it deserves to be read.

What I will not do is let that work stand in for evidence it never produced. Every human number here describes the body's own hormone responding to zinc. Nobody in that record was given thymulin. So the human data is real, and it is about a different question from the one a buyer is asking.

The habit I want readers to take from this one is simple: before weighing how good a study is, check which molecule went into the people in it. On thymulin that single question settles most of the argument.